Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.
Ondine Biomedical Inc. announced the exercise of options for 16,666 new ordinary shares, which will be admitted to trading on AIM. This development will increase the company’s total issued share capital to 442,054,809 ordinary shares, providing shareholders with a new denominator for calculating their interests. The move reflects Ondine’s ongoing efforts to enhance its market presence and operational capacity in the life sciences sector.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, including a nasal photodisinfection system approved in Canada and Europe, and under clinical trials in the US. Ondine’s products target various medical conditions such as chronic sinusitis, ventilator-associated pneumonia, and burns.
YTD Price Performance: 15.43%
Average Trading Volume: 256,507
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £41.41M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.